Motavizumab - New Biological Therapy for RSV Prevention

Resource  |  www.drugdevelopment-technology.com | Jun 9, 2008

News and project information on the Motavizumab - new biological therapy for RSV prevention by MedImmune.

http://www.drugdevelopment-technology.com/projects/nrimotovizumab/

Publications - Recent publications - UMC Utrecht

1: J Infect Dis. 2009 Sep 1;200(5):735-744 Intestinal Enterococcus faecium Colonization Improves Host Defense during Polymicrobial Peritonitis. Leendertse M, Willems RJ, Oei GA, Florquin S, Bonten MJ, van der Poll T.

http://www.umcutrecht.nl/subsite/medischemicrobiologie/Research/Publications/

CONNECTIONS

Resource  |  healthcare.zibb.com

Health Information Services, Namely Providing Information To Patients, Caregivers, and Healthcare Professionals On Topics of Therapy of Hiv Infection/Disease With Enfuvirtide, Treatment With Enfuvirtide, and Self-Management Skills For Patients Undergoing Treatment With Enfuvirtide

http://healthcare.zibb.com/trademark/connections/30794339

Pharmaceutical Licensing, Development, and Alliances | Pfizer: the world's largest research-based

Every global pharmaceutical company is pursuing business development opportunities to supplement the activities of its own RD organization. Unlike others, Pfizer is taking a new, highly disciplined approach to business development.

http://www.pfizer.com/research/licensing/our_vision.jsp

CTN :: Research Services :: Research Publications

Alter G, Tsoukas C M, Rouleau D, Cote P, Routy J P, Sekaly R P, and Bernard N F. "Assessment of Longitudinal Changes in Hiv-Specific Effector Activity in Subjects Undergoing Untreated Primary HIV Infection." AIDS 18, no. 15 (2004): 1979-89.

http://www.cheos.ubc.ca/e/research/journals2004.html

Siliciano, Robert F.

The benefits of HAART in reducing the morbidity and mortality are clearly documented, but major questions remain about how best to use this therapy and how to make it available to all who need it.

http://www.hopkinsmedicine.org/pharmacology/research/siliciano.html

Centre for Reviews and Dissemination - Our research

Zanamivir, oseltamivir and amantadine for the treatment of influenza: a systematic review and economic model to inform the update of NICE guidance no. 58 Background: Influenza (flu) is an illness caused by viruses.

http://www.york.ac.uk/inst/crd/projects/influenza_treatment.htm

CTN :: Research Services :: Research Publications

Allen U, Conway G, Forbes J, King S, Lapointe N, Marshall C, Gilmour J, Moore D, Stephens D, Wells G, Cassol C, and Read S. "Zidovudine Resistance among HIV-Infected Children: Association with Advanced Disease." Canadian Journal of Infectious Diseases ,no.12 (2001):113-15.

http://www.cheos.ubc.ca/e/research/journals2001.html

SYNAGIS

Resource  |  healthcare.zibb.com

Synagis® is a registered trademark used for Humanized Monoclonal Antibody Against Respiratory Syncytial Virus For Scientific Research Use Humanized Monoclonal Antibody Against Respiratory Syncytial Virus For Medical Clinical Use and owned by MedImmune, Inc..

http://healthcare.zibb.com/trademark/synagis/29630250

CTN :: Research Services :: Research Publications

Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. "Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker." J Acquir Immune Defic Syndr. 2007.

http://www.cheos.ubc.ca/e/research/journals2007.html